Literature DB >> 12760861

Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.

George G Zhanel1, Lorraine Palatnick, Kimberly A Nichol, Don E Low, Daryl J Hoban.   

Abstract

A total of 7,566 unique patient isolates of Haemophilus influenzae and 2,314 unique patient isolates of Moraxella catarrhalis were collected between October 1997 and June 2002 from 25 medical centers in 9 of the 10 Canadian provinces. Among the 7,566 H. influenzae isolates, 22.5% produced beta-lactamase, while 92.4% of the 2,314 M. catarrhalis isolates produced beta-lactamase. The incidence of beta-lactamase-producing H. influenzae isolates decreased significantly over the 5-year study period, from 24.2% in 1997-1998 to 18.6% in 2001-2002 (P < 0.01). The incidence of beta-lactamase-producing M. catarrhalis isolates did not change over the study period. The overall rates of resistance to amoxicillin and amoxicillin-clavulanate for H. influenzae were 19.3 and 0.1%, respectively. The rank order of cephalosporin activity based on the MICs at which 90% of isolates were inhibited (MIC(90)s) was cefotaxime > cefixime > cefuroxime > cefprozil > cefaclor. On the basis of the MICs, azithromycin was more active than clarithromycin (14-OH clarithromycin was not tested); however, on the basis of the NCCLS breakpoints, resistance rates were 2.1 and 1.6%, respectively. Rates of resistance to other agents were as follows: doxycycline, 1.5%; trimethoprim-sulfamethoxazole, 14.2%; and chloramphenicol, 0.2%. All fluoroquinolones tested, including the investigational fluoroquinolones BMS284756 (garenoxacin) and ABT-492, displayed potent activities against H. influenzae, with MIC(90)s of < or = 0.03 microg/ml. The MIC(90)s of the investigational ketolides telithromycin and ABT-773 were 2 and 4 microg/ml, respectively, and the MIC(90) of the investigational glycylcycline GAR-936 (tigecycline) was 4 microg/ml. Among the M. catarrhalis isolates tested, the resistance rates derived by using the NCCLS breakpoint criteria for H. influenzae were <1% for all antibiotics tested except trimethoprim-sulfamethoxazole (1.5%). In summary, the incidence of beta-lactamase-positive H. influenzae strains in Canada is decreasing (18.6% in 2001-2002), while the incidence of beta-lactamase-positive M. catarrhalis strains has remained constant (90.0% in 2001-2002).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12760861      PMCID: PMC155833          DOI: 10.1128/AAC.47.6.1875-1881.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group.

Authors:  L A Mandell; T J Marrie; R F Grossman; A W Chow; R H Hyland
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Hoban; G V Doern; A C Fluit; M Roussel-Delvallez; R N Jones
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

Review 3.  Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods.

Authors:  D E Low
Journal:  Infect Dis Clin North Am       Date:  1998-09       Impact factor: 5.982

4.  Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media?

Authors:  R Dagan; O Abramson; E Leibovitz; D Greenberg; R Lang; S Goshen; P Yagupsky; A Leiberman; D M Fliss
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

5.  Antibiotic use in a Canadian Province, 1995-1998.

Authors:  A G Carrie; C J Metge; G G Zhanel
Journal:  Ann Pharmacother       Date:  2000-04       Impact factor: 3.154

6.  A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States.

Authors:  R N Jones; M R Jacobs; J A Washington; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1997-03       Impact factor: 2.803

7.  Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998.

Authors:  G G Zhanel; J A Karlowsky; D E Low; D J Hoban
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

8.  Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997).

Authors:  G V Doern; R N Jones; M A Pfaller; K Kugler
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

9.  Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group.

Authors:  G G Zhanel; J A Karlowsky; L Palatnick; L Vercaigne; D E Low; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

10.  Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study.

Authors:  C Thornsberry; P T Ogilvie; H P Holley; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

View more
  20 in total

1.  Management of acute otitis media.

Authors:  S Forgie; G Zhanel; J Robinson
Journal:  Paediatr Child Health       Date:  2009-09       Impact factor: 2.253

2.  Antibiotic susceptibility of invasive Haemophilus influenzae strains in Canada.

Authors:  Michelle L Sill; Raymond S W Tsang
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

Review 3.  Canadian guidelines for acute bacterial rhinosinusitis: clinical summary.

Authors:  Alan Kaplan
Journal:  Can Fam Physician       Date:  2014-03       Impact factor: 3.275

Review 4.  The use of macrolides in treatment of upper respiratory tract infections.

Authors:  Aleksandra K Wierzbowski; Daryl J Hoban; Tamiko Hisanaga; Mel DeCorby; George G Zhanel
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

5.  Canadian clinical practice guidelines for acute and chronic rhinosinusitis.

Authors:  Martin Desrosiers; Gerald A Evans; Paul K Keith; Erin D Wright; Alan Kaplan; Jacques Bouchard; Anthony Ciavarella; Patrick W Doyle; Amin R Javer; Eric S Leith; Atreyi Mukherji; R Robert Schellenberg; Peter Small; Ian J Witterick
Journal:  Allergy Asthma Clin Immunol       Date:  2011-02-10       Impact factor: 3.406

Review 6.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 8.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Robert K Flamm; Paul R Rhomberg; Michael D Huband; David J Farrell
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

10.  Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.